| 1 |
Yin H, Jiang N, Shi W, Chi X, Liu S, Chen JL, Wang S. Development and Effects of Influenza Antiviral Drugs. Molecules 2021;26:810. [PMID: 33557246 DOI: 10.3390/molecules26040810] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 2 |
Li P, Du R, Chen Z, Wang Y, Zhan P, Liu X, Kang D, Chen Z, Zhao X, Wang L, Rong L, Cui Q. Punicalagin is a neuraminidase inhibitor of influenza viruses. J Med Virol 2021;93:3465-72. [PMID: 32827314 DOI: 10.1002/jmv.26449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 3 |
Loaiza-Cano V, Monsalve-Escudero LM, Filho CDSMB, Martinez-Gutierrez M, Sousa DP. Antiviral Role of Phenolic Compounds against Dengue Virus: A Review. Biomolecules 2020;11:E11. [PMID: 33374457 DOI: 10.3390/biom11010011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Du R, Cooper L, Chen Z, Lee H, Rong L, Cui Q. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. Antiviral Res 2021;190:105075. [PMID: 33872675 DOI: 10.1016/j.antiviral.2021.105075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Duncan MC, Onguéné PA, Kihara I, Nebangwa DN, Naidu ME, Williams DE, Balgi AD, Andrae-Marobela K, Roberge M, Andersen RJ, Niikura M, Ntie-Kang F, Tietjen I. Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus. Molecules 2020;25:E2903. [PMID: 32599753 DOI: 10.3390/molecules25122903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Vincent S, Arokiyaraj S, Saravanan M, Dhanraj M. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro. Front Mol Biosci 2020;7:613401. [PMID: 33425994 DOI: 10.3389/fmolb.2020.613401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Jantrapirom S, Hirunsatitpron P, Potikanond S, Nimlamool W, Hanprasertpong N. Pharmacological Benefits of Triphala: A Perspective for Allergic Rhinitis. Front Pharmacol 2021;12:628198. [PMID: 33995026 DOI: 10.3389/fphar.2021.628198] [Reference Citation Analysis]
|
| 8 |
Upadhyay S, Tripathi PK, Singh M, Raghavendhar S, Bhardwaj M, Patel AK. Evaluation of medicinal herbs as a potential therapeutic option against SARS-CoV-2 targeting its main protease. Phytother Res 2020;34:3411-9. [PMID: 32748969 DOI: 10.1002/ptr.6802] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 9 |
Li BH, Li ZY, Liu MM, Tian JZ, Cui QH. Progress in Traditional Chinese Medicine Against Respiratory Viruses: A Review. Front Pharmacol 2021;12:743623. [PMID: 34531754 DOI: 10.3389/fphar.2021.743623] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Terrier O, Slama-Schwok A. Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. Adv Exp Med Biol 2021;1322:195-218. [PMID: 34258742 DOI: 10.1007/978-981-16-0267-2_8] [Reference Citation Analysis]
|
| 11 |
Rezvanjoo Z, Raofie F. Nanoparticle Production of Terminalia Chebula Extracts by Expansion of Supercritical Solution (ESS). Int J Nanosci 2021;20:2150037. [DOI: 10.1142/s0219581x2150037x] [Reference Citation Analysis]
|
| 12 |
Mahaboob Ali AA, Bugarcic A, Naumovski N, Ghildyal R. Ayurvedic formulations: Potential COVID-19 therapeutics? Phytomedicine Plus 2022;2:100286. [DOI: 10.1016/j.phyplu.2022.100286] [Reference Citation Analysis]
|
